In this episode of Derms and Conditions, Dr. Jim Del Rosso and Dr. Gary Goldenberg discuss some of the highlights from the meeting. These include recent FDA approvals such as
bimekizumab for psoriasis and the triple topical combination for acne vulgaris, the newer  nonsteroidal topical agents, tapinarof and roflumilast, and their relevant clinical use, the 
significance of narrow-spectrum oral antibiotic therapy with sarecycline as compared to  other oral tetracycline with regard to antibiotic resistance, and physical devices such as
laser systems used to treat acne vulgaris.